Answer Critical Clinical Questions with Strategic Biomarker Solutions

A biomarker strategy defines how biomarkers are selected, tested, and used to support clinical objectives. It guides decisions around patient selection, endpoint definition, and data interpretation. A well-designed biomarker strategy helps reduce uncertainty, improve trial efficiency, and generate more meaningful clinical insights.

We support a wide range of biomarker types, including genomic, protein, cellular, and tissue-based biomarkers. These can be applied across multiple therapeutic areas and clinical phases, supporting everything from exploratory research through to validated clinical endpoints.

Reliable biomarker data depends on validated assays, standardized workflows, and consistent execution across laboratories. We use fit-for-purpose assay validation, harmonized processes, and centralized oversight to ensure data is reproducible, comparable, and aligned with study requirements.

Yes. We integrate data from multiple analytical platforms, including genomics, immunoassays, flow cytometry, and tissue analysis. This multi-modal approach provides a more complete understanding of biological mechanisms and supports more informed decision-making.

Biomarker strategy should be considered as early as possible, ideally during preclinical or early translational stages. Early planning helps ensure the right assays and endpoints are selected and reduces the risk of delays or data gaps later in development.

Biomarkers help identify patient subpopulations most likely to benefit from a given therapy. By linking biological characteristics with treatment response, they support more targeted clinical trials and enable precision medicine approaches.